☰

Ovarian Cancer Clinical Trials

Last reviewed: November 14, 2026

Ovarian cancer trials differ by histology, treatment setting, response to platinum chemotherapy and prior therapies. BRCA1/2, HRD, folate receptor alpha (FRα), HER2 and other results may open particular studies, but a biomarker alone does not establish eligibility. Use the setting guide below, then confirm the protocol and an open site with the study team.

Answer a few questions to find clinical trials matched to your specific Ovarian Cancer situation.

Results usually take about 15 minutes after you submit. Email is optional. No sign-up.

Find matching trials →

Current Clinical Trial Landscape

Registry snapshot, November 14, 2026: a worldwide ClinicalTrials.gov search for Ovarian Cancer, interventional studies, overall status Recruiting, returned 591 records. This is a search count, not 591 studies suitable for every person. It can include multi-cancer studies and other ovarian conditions; site and cohort availability differ. Open the filtered registry search.

Active research areas in 2026:

Approved treatment is not the same as trial eligibility. PARP maintenance depends on the specific drug, biomarker, prior therapy and local label; see the PARP guide. U.S. examples approved in 2026 for platinum-resistant disease include pembrolizumab plus paclitaxel, with or without bevacizumab for PD-L1 CPS ≥1 after one or two prior systemic regimens; and relacorilant plus nab-paclitaxel after one to three prior systemic regimens, including bevacizumab. Other approved options have their own restrictions. Ask your oncologist to compare standard care with a study in your setting.

Don't overlook tumor-agnostic trials. Some studies enroll by a specific biomarker — MSI-high / mismatch-repair-deficient, HER2, TMB-high, or an NTRK/RET fusion — rather than by cancer type. If your ovarian tumor carries one of these markers, you may qualify for trials that never mention “ovarian” in their title. Eligibility depends on your specific biomarker, not on all patients having it.

Our matcher screens these tumor-agnostic (basket) trials against your biology alongside ovarian-specific ones. Find trials matched to your biomarkers →

Start with your current treatment setting. Then add the details you know about your cancer and previous treatment. Use the guide below to find the relevant sections on this page.

Your starting pointWhere to look
You are newly diagnosed or planning initial treatment.Newly Diagnosed Disease: Treatment Followed by Maintenance and Surgery & Perioperative.
You have completed initial treatment and are discussing maintenance.First-Line Maintenance (After Platinum Response). Check each study’s required treatment history and response; the heading alone does not establish eligibility.
Your cancer has returned or progressed.Platinum-Sensitive Recurrence and Platinum-Resistant / Refractory. If you are unsure which description applies, ask your oncology team. You can also read our platinum-resistant ovarian cancer trial guide.
You know your histology or biomarker results.Read Specific Histologies and the biomarker requirements in individual study descriptions. Have your pathology and molecular reports available; different studies may require different tests or results.
You need a study within practical travel distance.Check the study’s listed sites and contact the study team about local enrollment. Overall recruitment status does not guarantee an open place at a particular site.

You do not need to know every answer before starting a search. Enter what you know and leave uncertain details as unknown. The study team must confirm eligibility and availability.

Selected Trials by Treatment Setting

All 32 cited registry records were checked November 14, 2026: 30 recruiting, one active but not recruiting, and one with unknown status. Non-recruiting/uncertain studies are separated below. These are selected examples, not the full registry result set. Overall recruitment does not guarantee an open local site or a place in a cohort.

First-Line Maintenance (After Platinum Response)

Maintenance follows initial treatment; the required platinum response, biomarkers and prior PARP exposure vary by protocol. Selected studies include:

Newly Diagnosed Disease: Treatment Followed by Maintenance

Platinum-Sensitive Recurrence

Platinum-Resistant / Refractory

Major unmet need. Two non-ADC regimens were approved in 2026 — pembrolizumab + paclitaxel for PD-L1-positive disease and relacorilant + nab-paclitaxel — and ADCs and novel agents are transforming the trial space:

→ For a dedicated guide to this setting — what platinum resistance means, today's approved options (Elahere/mirvetuximab for FRα-positive disease), the biomarkers that open trial doors, and recruiting trials organized by mechanism — see Platinum-Resistant Ovarian Cancer Clinical Trials.

Surgery & Perioperative

Specific Histologies

Studies Not Confirmed Open to New Enrollment

Contact the sponsor or study site to clarify availability; these entries are not counted as confirmed recruiting examples.

Novel Approaches

Frequently Asked Questions

How do I find ovarian cancer clinical trials?

Start with your histology, stage, prior treatments, platinum response and selected countries. Add BRCA1/2, HRD, FRα, HER2 or other test results you know. ClinTrialFinder can suggest studies to discuss with your oncologist, but the trial team determines eligibility and availability.

How many ovarian cancer trials are recruiting?

The November 14, 2026 worldwide ClinicalTrials.gov query for Ovarian Cancer, interventional studies and Recruiting status returned 591 records. This is a registry search count, not a count of suitable options for one person. The selected studies on this page have separate dated recruitment labels.

What trials are open for platinum-resistant ovarian cancer?

Selected recruiting examples include AZD5335 (NCT07218809), R-DXd (NCT06161025), sofetabart mipitecan Part A (NCT07213804), BL-B01D1 (NCT06994195), INCB123667 (NCT07214779), azenosertib (NCT07546500) and Olvi-Vec combinations (NCT05281471). Each has its own biomarker, prior-line and other criteria. Platinum-sensitive Rina-S second-line treatment (NCT07564141) is a different setting.

Which trials depend on BRCA, HRD or previous PARP treatment?

Examples include first-line HRD-positive maintenance NCT07472140 and olaparib-duration study NCT06580314, which requires BRCA mutation or HRD-positive disease and no prior PARP inhibitor. MITO 35B (NCT05255471) instead studies a defined recurrence setting after first-line PARP maintenance and secondary cytoreduction. Sac-TMT study NCT07318558 addresses non-HRD-positive first-line maintenance. Do not treat these as interchangeable options.

Are there studies for low-grade serous or clear cell ovarian cancer?

Yes. Recurrent low-grade serous disease is studied in RAMP-301 (NCT06072781). LEPRE (NCT05601700) studies letrozole versus chemotherapy after primary surgery in newly diagnosed ER/PgR-positive Stage III/IV low-grade serous disease. INVIGORATE (NCT07002346) studies QL1706 with bevacizumab in first-line ovarian clear cell carcinoma. Histology and treatment timing matter.

Additional sources: NCI description of QL1706 as an antibody mixture; sponsor identification of OVATION 3. Registry descriptions and recruitment labels were checked against the linked study records.

Find Ovarian Cancer Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your BRCA/HRD status, histology, and treatment history.

Find Matching Trials